WO2001065994A3 - Methode et materiel d'evaluation de la faculte de reponse de patients cancereux a une chimiotherapie a antifolate - Google Patents

Methode et materiel d'evaluation de la faculte de reponse de patients cancereux a une chimiotherapie a antifolate Download PDF

Info

Publication number
WO2001065994A3
WO2001065994A3 PCT/IL2001/000212 IL0100212W WO0165994A3 WO 2001065994 A3 WO2001065994 A3 WO 2001065994A3 IL 0100212 W IL0100212 W IL 0100212W WO 0165994 A3 WO0165994 A3 WO 0165994A3
Authority
WO
WIPO (PCT)
Prior art keywords
kit
cancer patients
antifolate
assessing responsiveness
chemotherapy
Prior art date
Application number
PCT/IL2001/000212
Other languages
English (en)
Other versions
WO2001065994A2 (fr
Inventor
Yehuda Assaraf
Statvit Drori
Original Assignee
Technion Res & Dev Foundation
Yehuda Assaraf
Statvit Drori
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technion Res & Dev Foundation, Yehuda Assaraf, Statvit Drori filed Critical Technion Res & Dev Foundation
Priority to US09/936,764 priority Critical patent/US20040101834A1/en
Priority to AU2001240998A priority patent/AU2001240998A1/en
Publication of WO2001065994A2 publication Critical patent/WO2001065994A2/fr
Publication of WO2001065994A3 publication Critical patent/WO2001065994A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Méthode d'évaluation de la faculté de réponse d'un patient cancéreux à une chimiothérapie contenant de l'antifolate, la méthode est mise à exécution par recherche d'une mutation ou de mutations dans un gène porteur de folates réduits (RFC) dans des cellules dérivées du patient.
PCT/IL2001/000212 2000-03-06 2001-03-06 Methode et materiel d'evaluation de la faculte de reponse de patients cancereux a une chimiotherapie a antifolate WO2001065994A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US09/936,764 US20040101834A1 (en) 2001-03-06 2001-03-06 Method of and kit for assessing responsiveness of cancer patients to antifolate chemotherapy
AU2001240998A AU2001240998A1 (en) 2000-03-06 2001-03-06 Method of and kit for assessing responsiveness of cancer patients to antifolate chemotherapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51967300A 2000-03-06 2000-03-06
US09/519,673 2000-03-06

Publications (2)

Publication Number Publication Date
WO2001065994A2 WO2001065994A2 (fr) 2001-09-13
WO2001065994A3 true WO2001065994A3 (fr) 2002-01-17

Family

ID=24069301

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2001/000212 WO2001065994A2 (fr) 2000-03-06 2001-03-06 Methode et materiel d'evaluation de la faculte de reponse de patients cancereux a une chimiotherapie a antifolate

Country Status (2)

Country Link
AU (1) AU2001240998A1 (fr)
WO (1) WO2001065994A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040023375A1 (en) 2002-07-30 2004-02-05 Precision Therapeutics, Inc. Method for preparing cell cultures from biological specimens for chemotherapeutic and other assays
US20040072722A1 (en) 2002-10-10 2004-04-15 Kornblith Paul L. Methods for assessing efficacy of chemotherapeutic agents
US7582282B2 (en) * 2003-08-29 2009-09-01 Prometheus Laboratories Inc. Methods for optimizing clinical responsiveness to methotrexate therapy using metabolite profiling and pharmacogenetics
WO2010055525A1 (fr) * 2008-11-17 2010-05-20 Technion Research & Development Foundation Ltd. Procédé pour prédire la réactivité d'un patient à une thérapie par antifolate
US20110014644A1 (en) * 2009-06-22 2011-01-20 Precision Therapeutics, Inc. Methods for predicting a cancer patient's response to antifolate chemotherapy

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GUO W. ET AL.: "Mechanisms of methotrexate resistance in osteosarcoma", CLINICAL CANCER RESEARCH, vol. 5, March 1999 (1999-03-01), pages 621 - 627, XP002944952 *
JANSEN G. ET AL.: "A structurally altered human reduced folate carrier with increased folic acid trransport mediates a novel mechanism of antifolate resistance", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 46, 13 November 1998 (1998-11-13), pages 30189 - 30198, XP002944953 *
ROY K. ET AL.: "A single amino acid difference within the folate transporter encoded by the murine RFC-1 gene selectivity alters its interaction with folate analogues", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 5, 30 January 1998 (1998-01-30), pages 2526 - 2531, XP002944954 *
TAKEMURA Y. ET AL.: "Biological activity and intracellular metabolism of ZD1694 in human leukemia cell lines with different resistance mechanisms to antifolate drugs", JAPANESE JOURNAL OF CANCER RESEARCH, vol. 87, July 1996 (1996-07-01), pages 773 - 780, XP002944955 *

Also Published As

Publication number Publication date
AU2001240998A1 (en) 2001-09-17
WO2001065994A2 (fr) 2001-09-13

Similar Documents

Publication Publication Date Title
EP2289940A3 (fr) Traitement de maladie métastatique
CA2400554A1 (fr) Derives de pyrimidine-4-one utilises comme inhibiteurs de ldl-pla2
AU3928999A (en) Novel n-oxides
WO2004029219A3 (fr) Interference arn basee sur les cellules, et procedes et compositions s'y rapportant
EP1176210A4 (fr) Preparation contenant un extrait de cellules pour la synthese d'une proteine exempte de cellules, et moyen de synthese d'une proteine exempte de cellules
WO2001023592A3 (fr) Procede de fabrication de proteines recombinantes a l'aide d'inhibiteurs d'apoptose
WO2004056827A3 (fr) Derives de pyrrolo-pyrazoles substitues constituant des inhibiteurs de kinases
WO2004007679A3 (fr) Potentialisation des cellules dendritiques
PL372107A1 (en) Over-expression of extremozyme genes in pseudomonads and closely related bacteria
WO1998037181A3 (fr) Gene de sous-unite catalytique de telomerase et proteine codee
WO2004000094A3 (fr) Marqueurs predictifs utilises dans le traitement du cancer
AU2003226676A1 (en) Methods and compositions for the identification, assessment, and therapy of small cell lung cancer
WO2003014303A3 (fr) Interactions moleculaires dans les cellules
RS20050876A (en) Novel pyridopyrazines and use thereof as kinase m odulators
WO2003065985A3 (fr) Utilisations d'une cytokine mammifere et reactifs associes
AU3307999A (en) Phosphodiesterase 10
WO2001061017A3 (fr) Cytokines modifiees utilisees dans le traitement du cancer
WO2001065994A3 (fr) Methode et materiel d'evaluation de la faculte de reponse de patients cancereux a une chimiotherapie a antifolate
WO2001072970A3 (fr) Methodes de preparation et d'utilisation de cellules souches epidermiques
GB9825096D0 (en) Cells,culture methods and their uses
WO2000058352A3 (fr) Gene d'orge pour reductase de thioredoxine et de thioredoxine nadp
NO20012100L (no) Pyrano-, piperidino- og tiopyranoforbindelser og fremgangsmåter ved anvendelse
WO2004041297A3 (fr) Cytokines modifiees a utiliser dans la therapie contre le cancer
AU6768900A (en) Use of ginkgo extract
WO2005076984A3 (fr) Gene de la thymidylate synthase et metastase

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 09936764

Country of ref document: US

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)